Enliven Therapeutics (NASDAQ:ELVN) Trading 4.7% Higher

Enliven Therapeutics, Inc. (NASDAQ:ELVN)’s stock price rose 4.7% on Thursday . The stock traded as high as $18.12 and last traded at $18.12. Approximately 39,716 shares were traded during trading, a decline of 81% from the average daily volume of 214,132 shares. The stock had previously closed at $17.30.

Analyst Upgrades and Downgrades

Separately, Mizuho initiated coverage on Enliven Therapeutics in a research note on Tuesday, April 9th. They set a “buy” rating and a $34.00 target price on the stock.

Enliven Therapeutics Stock Performance

The company has a 50 day simple moving average of $17.05 and a two-hundred day simple moving average of $14.36.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Thursday, March 14th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.09. As a group, equities research analysts forecast that Enliven Therapeutics, Inc. will post -2.16 earnings per share for the current year.

Insider Activity at Enliven Therapeutics

In related news, major shareholder 5Am Partners Vi, Llc sold 500,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $15.00, for a total value of $7,500,000.00. Following the completion of the sale, the insider now owns 771,983 shares of the company’s stock, valued at approximately $11,579,745. The sale was disclosed in a document filed with the SEC, which is available at this link. In related news, COO Anish Patel sold 4,875 shares of the business’s stock in a transaction that occurred on Monday, January 22nd. The stock was sold at an average price of $15.13, for a total value of $73,758.75. Following the completion of the sale, the chief operating officer now owns 17,222 shares of the company’s stock, valued at approximately $260,568.86. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder 5Am Partners Vi, Llc sold 500,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $15.00, for a total value of $7,500,000.00. Following the sale, the insider now directly owns 771,983 shares of the company’s stock, valued at approximately $11,579,745. The disclosure for this sale can be found here. In the last quarter, insiders sold 763,661 shares of company stock valued at $13,213,762. 45.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Enliven Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC bought a new stake in Enliven Therapeutics during the first quarter worth approximately $36,000. Ameritas Investment Partners Inc. bought a new stake in Enliven Therapeutics during the second quarter worth approximately $39,000. AJOVista LLC bought a new stake in Enliven Therapeutics during the fourth quarter worth approximately $28,000. Royal Bank of Canada boosted its position in Enliven Therapeutics by 532.7% during the second quarter. Royal Bank of Canada now owns 3,075 shares of the company’s stock worth $63,000 after purchasing an additional 2,589 shares during the period. Finally, China Universal Asset Management Co. Ltd. bought a new stake in Enliven Therapeutics during the fourth quarter worth approximately $66,000. Institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.